Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil

       Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil

PR Newswire

HAYWARD, Calif., Feb. 5, 2013

HAYWARD, Calif., Feb. 5, 2013 /PRNewswire/ --Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH)today announced that Senior Vice President of Product
Development Georgina Kilfoil has notified the company she will leave the
company effective February 15, 2013 to pursue other opportunities.

"The Board and management of Anthera would like to thank Georgina for her
years of dedicated service. Georgina's exemplary leadership and experience was
instrumental in the advancement of Anthera's development programs. Her
tireless efforts brought us to the starting line of our BRIGHT-SC phase 2
study for IgA Nephropathy and CHABLIS-SC phase 3 study for systemic lupus
erythematosus, which we are excited to get underway this year," said Paul F.
Truex, Anthera's President and Chief Executive Officer. "We wish Georgina all
the best as she seeks to repeat her success in future endeavors."

Dr. Colin Hislop, Anthera's Senior Vice President and Chief Medical Officer,
will continue to oversee all product development related activities for
blisibimod.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements include statements about the Company's expectations with respect to
its proposed offering, including its intention to offer and sell shares, its
intention to grant the underwriters an option to purchase additional shares
and its intended use of proceeds from the offering. Such statements are based
on the Company's expectations as of the date of this press release and are
subject to certain risks and uncertainties that could cause actual results to
differ materially, including but not limited to the risks and uncertainties
associated with market conditions and the satisfaction of customary closing
conditions related to the proposed offering, as well as those set forth in the
Company's public filings with the SEC, including the Company's Annual Report
on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form
10-Q for the quarter ended September 30, 2012. The Company disclaims any
intent or obligation to update any forward-looking statements, whether because
of new information, future events or otherwise, except as required by
applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or
510.856.5586.

SOURCE Anthera Pharmaceuticals, Inc.

Website: http://www.anthera.com